DEFINITIVE CONTRACT
Active75F40126C00197
Department of Health and Human Services › Food and Drug Administration › FDA OFFICE OF ACQ GRANT SVCS
$293.8K
obligated · signed 6 days ago
FY26C3BP6 - ADVANCING THE DEVELOPMENT OF EXTERNAL CONTROLS FOR INVASIVE FUNGAL I
Performance timeline
Start
Sep 30, 2026
End
Sep 29, 2028
with all options
Loading status
Estimated start: Sep 29, 2027
CARELANE LLC
Contract 75F40126C00197
UEI
WVBLJFGMAU46
Parent Company
CARELANE LLC
Capabilities & Certifications
Headquarters Location
Congressional District: 13
Current Obligation
$293,829
Base + Exercised Options
$293,829
Total Ceiling Value
$293,829
Contract Type
FIRM FIXED PRICE
Multi-Year Contract
NO
NAICS
RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSC
HEALTH R&D SERVICES; HEALTH CARE - OTHER; BASIC RESEARCH
Place of Performance
Congressional District: 13
Awarding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Funding Agency
Top-tier agency
Food and Drug Administration
Sub-tier agency
FDA OFFICE OF ACQ GRANT SVCS
Office
Solicitation procedures, competition exceptions, labor standards and account totals.